Recent Achievements About Targeted Alpha Therapy-Based Targeting Vectors and Chelating Agents

Recent Achievements About Targeted Alpha Therapy-Based Targeting Vectors and Chelating Agents Publisher Pubmed

Farzipour S¹ ; Shaghaghi Z^{2, 3} ; Abbasi S⁴ ; Albooyeh H⁵ ; Alvandi M⁶

Show Affiliations

1. Cardiovascular Diseases Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
2. Medicinal Plants and Natural Products Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
3. Department of Nuclear Medicine and Molecular Imaging, Clinical Development Research Unit of Farshchian Heart Center, Hamadan University of Medical Sciences, Hamadan, Iran
4. Department of Radiology, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5. Department of Nuclear Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
6. Department of Nuclear Medicine and Molecular Imaging, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

Source: Anti-Cancer Agents in Medicinal Chemistry Published:2022

Abstract

One of the most rapidly growing options in the management of cancer therapy is Targeted Alpha Therapy (TAT) through which lethal α-emitting radionuclides conjugated to tumor-targeting vectors selectively deliver high amount of radiation to cancer cells.225Ac,212Bi,211At,213Bi, and223Ra have been investigated by plenty of clinical trials and preclinical researches for the treatment of smaller tumor burdens, micro-metastatic disease, and post-surgery resid-ual disease. In order to send maximum radiation to tumor cells while minimizing toxicity in normal cells, a high affini-ty of targeting vectors to cancer tissue is essential. Besides that, the stable and specific complex between chelating agent and α-emitters was found as a crucial parameter. The present review was planned to highlight recent achievements about TAT-based targeting vectors and chelating agents and provide further insight for future researches. © 2022 Bentham Science Publishers.

2. Application of Radiolabeled Peptides in Tumor Imaging and Therapy, Life Sciences (2020)

3. Astatine-211 Radiopharmaceuticals; Status, Trends, and the Future, Current Radiopharmaceuticals (2024)

Experts (# of related papers)

View all Related Experts

Mehdi Shafee Ardestani (1)

Massoud Amanlou (1)

Style	Citing Format
MLA	Farzipour S, et al.. "Recent Achievements About Targeted Alpha Therapy-Based Targeting Vectors and Chelating Agents." Anti-Cancer Agents in Medicinal Chemistry, vol. 22, no. 8, 2022, pp. 1496-1510.
APA	Farzipour S, Shaghaghi Z, Abbasi S, Albooyeh H, Alvandi M (2022). Recent Achievements About Targeted Alpha Therapy-Based Targeting Vectors and Chelating Agents. Anti-Cancer Agents in Medicinal Chemistry, 22(8), 1496-1510.
Chicago	Farzipour S, Shaghaghi Z, Abbasi S, Albooyeh H, Alvandi M. "Recent Achievements About Targeted Alpha Therapy-Based Targeting Vectors and Chelating Agents." Anti-Cancer Agents in Medicinal Chemistry 22, no. 8 (2022): 1496-1510.
Harvard	Farzipour S et al. (2022) 'Recent Achievements About Targeted Alpha Therapy-Based Targeting Vectors and Chelating Agents', Anti-Cancer Agents in Medicinal Chemistry, 22(8), pp. 1496-1510.
Vancouver	Farzipour S, Shaghaghi Z, Abbasi S, Albooyeh H, Alvandi M. Recent Achievements About Targeted Alpha Therapy-Based Targeting Vectors and Chelating Agents. Anti-Cancer Agents in Medicinal Chemistry. 2022;22(8):1496-1510.
BibTex	@article{ author = {Farzipour S and Shaghaghi Z and Abbasi S and Albooyeh H and Alvandi M}, title = {Recent Achievements About Targeted Alpha Therapy-Based Targeting Vectors and Chelating Agents}, journal = {Anti-Cancer Agents in Medicinal Chemistry}, volume = {22}, number = {8}, pages = {1496-1510}, year = {2022} }
RIS	TY - JOUR AU - Farzipour S AU - Shaghaghi Z AU - Abbasi S AU - Albooyeh H AU - Alvandi M TI - Recent Achievements About Targeted Alpha Therapy-Based Targeting Vectors and Chelating Agents JO - Anti-Cancer Agents in Medicinal Chemistry VL - 22 IS - 8 SP - 1496 EP - 1510 PY - 2022 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract